

TABLE OF CONTENTS

| | |
|--|-----------------|
| Certificate | iii |
| Declaration by the Candidate | iv |
| Copyright Transfer Certificate | v |
| Acknowledgement | vi-viii |
| Table of Contents | ix-xiii |
| LIST OF FIGURES | xiv-xvii |
| LIST OF TABLES | xviii |
| LIST OF ABBREVIATIONS | xix-xx |
| PREFACE | xxi-xxiv |
| CHAPTER 1: Introduction and Literature Review | 1-54 |
| 1.1 Introduction | 1 |
| 1.2 Chemotherapy Induced Neuropathic Pain | 4 |
| 1.2.1 CINP Manifestations: Unique Symptomatology | 5 |
| 1.2.2 Neural Basis of Chemotherapy-Induced Neuropathic Pain | 7 |
| 1.2.2.1 Peripheral sensitization | 7 |
| 1.2.2.2 Central sensitization | 9 |
| 1.3 Chemotherapeutic agents and their mechanisms | 10 |
| 1.3.1 Platinum- induced neuropathic pain | 13 |
| 1.3.2 Epothilones-induced neuropathic pain | 14 |
| 1.3.3 Thalidomide-induced peripheral neuropathy | 15 |
| 1.3.4 Vinca alkaloids-induced neuropathic pain | 17 |
| 1.3.5 Protease Inhibitors-induced neuropathic pain | 19 |
| 1.3.6 Paclitaxel-Induced Neuropathic Pain | 21 |
| 1.3.6.1 Axonal transport disruption | 22 |
| 1.3.6.2 Mitochondrial dysfunction | 23 |
| 1.3.6.3 Increased ion channel activity | 24 |
| 1.3.6.4 Role of NMDA receptor system in the neurobiology of CINP | 28 |
| 1.3.6.5 Neuronal injury and inflammation | 29 |

| | |
|--|--------------|
| 1.4 Therapeutics for the treatment of CINP and their limitations | 31 |
| 1.4.1 Preventive Measures for Minimizing Functional Impairment in CINP | 31 |
| 1.4.2 Pharmacological interventions | 31 |
| 1.4.2.1 Selective serotonin-noradrenalin reuptake inhibitors | 32 |
| 1.4.2.2 Tricyclic antidepressants | 33 |
| 1.4.2.3 Anticonvulsants | 33 |
| 1.4.2.4 Opioids | 34 |
| 1.4.2.5 Topical Agents | 35 |
| 1.4.2.6 Cannabinoids | 36 |
| 1.4.3 Combination Therapies | 38 |
| 1.4.4 Limitations associated with these therapeutic options | 39 |
| 1.5 G-Protein Coupled Receptors | 40 |
| 1.5.1 GPCRS and Pain modulation | 41 |
| 1.6 Peripheral GPCRs: A Potential Target for Chronic Pain | 43 |
| 1.6.1 Mu-opioid receptors | 45 |
| 1.6.1.1 Mechanism of peripheral Opioid Analgesia | 46 |
| 1.6.1.2 Loperamide, a peripheral mu opioid agonist | 47 |
| 1.6.1.3 Dermorphin [d-Arg ² , Lys ⁴] (1–4) amide (DALDA), a preferential peripheral mu opioid agonist | 49 |
| 1.6.2 Cannabinoid receptors | 51 |
| 1.6.2.1 Mechanism of peripheral cannabinoid analgesia | 51 |
| 1.6.2.2 CB13 (CRA13 or SAB-378): peripherally restricted dual cannabinoid receptor agonist | 53 |
| CHAPTER 2: Rationale, Objectives and Plan of Work | 55-59 |
| 2.1 Rationale | 55 |
| 2.2 Objectives | 56 |
| 2.3 Plan of work | 57 |
| 2.3.1 Study I | 57 |
| 2.3.2 Study II | 58 |
| 2.2.3 Study III | 59 |

| | |
|---|--------------|
| CHAPTER 3: Materials & Methods | 60-76 |
| 3.1 Drugs, chemicals and antibodies | 60 |
| 3.2 Equipment and software | 63 |
| 3.3 In-vivo studies | 65 |
| 3.3.1 Experimental animals | 65 |
| 3.3.2 Ethical committee approval | 65 |
| 3.3.3 Paclitaxel Induced Chronic Pain Model | 65 |
| 3.3.4 Behavioural Analysis | 67 |
| 3.3.4.1 von-Frey hair Test: Mechanical allodynia | 67 |
| 3.3.4.2 Pinprick test: Mechanical Hyperalgesia | 67 |
| 3.3.4.3 Acetone evaporation test: Cold Allodynia | 68 |
| 3.3.4.4 Ice floor test: Cold Hyperalgesia | 68 |
| 3.3.4.5 Conditioned place preference: Spontaneous ongoing pain assay | 68 |
| 3.3.5 Behavioral neurotoxicity assays | 69 |
| 3.3.5.1 Open field test | 69 |
| 3.3.5.2 Rota-rod test | 70 |
| 3.3.6 Tissue harvesting and storage | 70 |
| 3.3.7 Biochemical assays | 71 |
| 3.3.7.1 Lipid peroxidation | 71 |
| 3.3.7.2 Nitrite estimation | 71 |
| 3.3.7.3 Glutathione estimation | 71 |
| 3.3.8 Molecular biology studies | 72 |
| 3.3.8.1 Western blot analysis | 72 |
| 3.3.8.2 Reverse transcription polymerase chain reaction (RT-PCR) analysis | 74 |
| 3.3.9 Statistical analysis | 76 |
| CHAPTER 4: Loperamide, a peripheral Mu-Opioid receptor agonist, attenuates chemotherapy-induced neuropathic pain in rats | 77-98 |
| 4.1 Introduction | 77 |
| 4.2 Experimental procedure | 79 |

| | |
|--|---------------|
| 4.3 Results and discussion | 80 |
| 4.3.1 Activation of peripheral MOR attenuates pain-like behaviour in PTX-induced neuropathic rats | 80 |
| 4.3.2 Activation of peripheral MOR attenuates ongoing pain in PTX-induced neuropathic rats | 83 |
| 4.3.3 Loperamide treatment does not affect locomotor activity and motor coordination of rats | 86 |
| 4.3.4 Loperamide reversed oxido-nitrosative stress in sciatic nerve of PTX-induced neuropathic rats | 88 |
| 4.3.5 Loperamide downregulates mRNA and protein expressions of VGSCs and TRP channels in the dorsal root ganglion of neuropathic rats | 90 |
| 4.3.6 Loperamide attenuates neuropathic pain in rats via NR2B independent mechanism | 92 |
| 4.3.7 Loperamide suppressed expression of ICAM1 and CGRP but not IBA1 in spinal cord of CINP rats | 93 |
| 4.3.8 Loperamide attenuates central sensitization by modulating inflammatory signalling in DRG and spinal cord of PTX induced neuropathic rats | 96 |
| 4.4 Outcomes | 98 |
| CHAPTER 5: Peripheral mu-opioid receptor activation by dermorphin [D-Arg2, Lys4] (1–4) amide alleviates behavioral and neurobiological aberrations in rat model of chemotherapy -induced neuropathic pain | 99-116 |
| 5.1 Introduction | 99 |
| 5.2 Experimental design | 101 |
| 5.3 Results and discussion | 102 |
| 5.3.1 Peripheral MOR activation attenuates allodynia and hyperalgesia in paclitaxel-induced neuropathic rats | 102 |
| 5.3.2 DALDA attenuates spontaneous pain in paclitaxel-induced neuropathic rats | 105 |
| 5.3.3 DALDA treatment didn't induce CNS toxicities in rats | 106 |
| 5.3.4 DALDA attenuates oxido-nitrosative stress in sciatic nerve of paclitaxel-induced neuropathic rats | 108 |
| 5.3.5 DALDA alleviates CINP by downregulating ion channels and NR2B expressions in DRG of neuropathic rats | 109 |

| | |
|---|----------------|
| 5.3.6 DALDA treatment attenuates microglia activation in spinal cord of neuropathic rats | 112 |
| 5.3.7 DALDA attenuates neuroinflammation by inhibiting release of pro-inflammatory cytokines and neuropeptides | 114 |
| 5.4 Outcomes | 116 |
| CHAPTER 6: Activation of peripheral cannabinoid receptors by CB-13 leads to modality specific attenuation of Chemotherapy-induced Neuropathic Pain | 117-136 |
| 6.1 Introduction | 117 |
| 6.2 Experimental design | 118 |
| 6.3 Results and discussion | 119 |
| 6.3.1 Peripheral CBR activation attenuates allodynia like behaviour in paclitaxel-induced neuropathic rats | 119 |
| 6.3.2 Peripheral CBR activation does not attenuate hyperalgesia like behaviour in paclitaxel-induced neuropathic rats | 122 |
| 6.3.3 CB13 does not attenuate spontaneous pain in paclitaxel-induced neuropathic rats | 124 |
| 6.3.4 CB13 treatment didn't induce CNS toxicities in rats | 125 |
| 6.3.5 CB13 restores GSH levels but fails to suppress oxido-nitrosative parameters in the sciatic nerve of paclitaxel-induced neuropathic rats | 127 |
| 6.3.6 CB13 alleviates CINP by downregulating TRP channels, VGCCs and NR2B expressions in DRG of neuropathic rats | 128 |
| 6.3.7 CB13 treatment attenuates microglia activation in spinal cord of neuropathic rats | 131 |
| 6.3.8 CB13 attenuates neuroinflammation by inhibiting release of pro-inflammatory cytokines and neuropeptides | 133 |
| 6.4 Outcomes | 136 |
| CHAPTER 7: Summary & Conclusions | 137-142 |
| 7.1 Summary | 137 |
| 7.2 Conclusion | 140 |
| 7.3 Limitations and outlook for future work | 141 |
| References | 143-172 |
| List of Publications | 173-176 |
| Brief Bio-Sketch | 177-178 |